Blackstone bankrolls supply chain player's deal spree with $275M
A wheeling and dealing Blackstone crew isn’t limiting its focus on drug — or even medtech — R&D. In its latest deal, the private equity firm is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
